Effective reduction of postprandial hyperglycemia preferred medication - Miglinide calcium capsule


Has anyone ever told you: diabetes has always been with us.
According to China's epidemiological research:
Every 10 Chinese adults, there is 1 diabetic.
1 out of every 2 Chinese adults is a diabetic.
What's worse, the probability of diabetes is increasing among people under the age of 40, as well as pregnant women, and even primary and secondary school students in China.
Diabetes is a group of metabolic diseases characterized by high blood sugar. Hyperglycemia, on the other hand, is caused by defective insulin secretion or its impaired biological action, or both. The hyperglycemia that persists over time in diabetes leads to chronic damage and dysfunction of various tissues, especially the eyes, kidneys, heart, blood vessels, and nerves.
At present, there is no cure for diabetes, but the good news is that diabetes can be controlled through effective treatments, one of the more critical is medication.
About diabetes clinical oral medication, that must have Miglinide calcium capsules.
 
The latest generation of mealtime blood glucose regulator--Miglinide Calcium Capsules
(Approval number: State Drug License H20153263, National Medical Insurance Class B)
Miglinide is a new structure of oral fast-acting meal-liquid hypoglycemic drug. Miglinide is the third new benzoic acid derivative hypoglycemic drug after Repaglinide and Naglinide, which is a new generation of non-sulfonylurea insulin secretion promoter, and is known as "meal-time blood glucose regulator".
Diabetes requires strict control of blood glucose levels during treatment, especially in terms of dietary control, if a little careless, improper diet may lead to postprandial blood glucose increase, resulting in aggravation of the condition.
Miglinide calcium capsule is to improve postprandial hyperglycemia in patients with type 2 diabetes.
Main ingredients: Miglinide Calcium.The main function is to improve postprandial hyperglycemia in patients with type 2 diabetes.
The drug is aimed at patients who cannot effectively control their blood glucose by diet and exercise therapy or patients who still cannot effectively control their blood glucose after the addition of α-glucosidase inhibitors on top of diet and exercise therapy.
Pharmacological action: lies in the component Miglinide and pancreatic islet β-cell membrane sulfonylurea receptor binding, inhibition of pancreatic islet β-cell membrane ATP-sensitive K + channel, resulting in cellular depolarization, the intracellular Ca2 + concentration increases, thus promoting insulin secretion, lowering blood glucose.
Although it is to control postprandial blood glucose, patients need to take the drug before meals.
Dosage: Take orally within 5 minutes before meal. Usually 10mg per time, 3 times a day for adults. Dosage may be adjusted at the patient's discretion according to the therapeutic effect.
In addition, Miglinide Calcium Capsules offer the following 8 advantages
1, national exclusive dosage form, 2017 new version of the national medical insurance;
2, faster onset of action, shorter duration of action;
3, stronger efficacy, lower blood glucose and HbA1c levels;
4, high receptor selectivity, protect pancreatic islet cells;
5、Flexible drug delivery, known as "extracorporeal pancreas";
6, early and mild diabetes patients with a line of therapeutic drugs;
7, good tolerance, can be used for a long time;
8, treatment of type 2 diabetes, reduce postprandial blood glucose.
 
At present, the market demand for oral diabetes medication is still expanding. Many varieties such as acarbose, glimepiride, metformin, etc. with the implementation of the national band purchasing, there is no more agent space to operate. Then the advantages of our Miguel have become apparent, many agents have locked the field, and we are just an easy to volume, sales are guaranteed diabetes medication. Then Miglinide calcium capsules must be your ideal choice, in addition to the outstanding effect of the product itself, but also has many advantages. What's more, the investment enterprise will also provide cooperative agents academic support, high open cashback, short cycle speed and other lucrative service support.

Other Dynamics


Mitiglinide Calcium Capsules The new version of the medical insurance catalog of clinical application advantages of analysis

Early-phase insulin secretion defect is a characteristic manifestation of abnormal insulin secretion pattern in type 2 diabetes mellitus patients, and insulinotropic agents have an important role in the treatment of type 2 diabetes mellitus. Coinciding with the successful entry of the new mealtime insulinotropic agent, Miglinide calcium, into the new version of the national health insurance catalog, Diabetes International invited Prof. Mou Yiming of the General Hospital of the Chinese People's Liberation Army to explain the advantages of the application and the applicable population of Miglinide calcium, and to analyze the benefits that will be provided to the patients after its entry into the health insurance.


Explanation of pharmacological effects of Miglinide calcium in the new version of the medical insurance catalog

Defective β-cell insulin secretion is one of the central aspects of the pathogenesis of type 2 diabetes. Coinciding with the successful entry of the new mealtime insulinotropic agent, Miglinide calcium, into the new version of the National Health Insurance Catalog, Diabetes International invited Prof. Zhigang Zhao of the Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, to make a professional analysis of the advantages of the action of the new insulinotropic agent from the perspective of pharmacology.


Effective reduction of postprandial hyperglycemia preferred medication - Miglinide calcium capsule

What's worse, the probability of diabetes is increasing among people under the age of 40, as well as pregnant women, and even primary and secondary school students in China.


Golden single product, the heart and brain with treatment - Yixinone dispersible tablets

According to the World Health Organization: the number of people suffering from cardiovascular disease in China has reached 300 million, i.e. 2 out of every 10 adults suffer from cardiovascular disease.


Pioglitazone is the preferred drug for the treatment of type 2 diabetes mellitus.

Diabetes mellitus is a disorder of sugar, fat and protein metabolism caused by a defect in insulin secretion or a decrease in the sensitivity of body tissues and cells to insulin. It is characterized by high blood glucose and is often characterized by excessive urination, drinking, eating and wasting, i.e. "three more and one less".


Drug procurement "national first standard" came drug companies or face different situations

On November 15, the full text of the "4+7" Cities Drug Centralized Purchasing Document was published. With the consent of the Central Committee for Comprehensively Deepening Reform, the State organized a pilot centralized procurement of medicines, and the scope of the pilot area is Beijing, Tianjin, Shanghai, Chongqing, as well as Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu, Xi'an, and other 11 cities (referred to as the "4 + 7 cities"). According to the procurement documents, the first batch of banded procurement catalog totaled 31 varieties, including cefuroxime tablets, escitalopram oxalate tablets, and resuvastatin calcium tablets that have been full of three enterprises through consistency evaluation.